Cyclo Therapeutics (NASDAQ:CYTH) Receives New Coverage from Analysts at Ascendiant Capital Markets

Ascendiant Capital Markets began coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH) in a report published on Monday morning, Benzinga reports. The brokerage issued a buy rating and a $2.60 target price on the stock.

Cyclo Therapeutics Price Performance

Cyclo Therapeutics stock opened at $1.26 on Monday. The business has a 50 day moving average of $1.51 and a 200-day moving average of $1.46. The company has a market capitalization of $36.18 million, a P/E ratio of -0.96 and a beta of -0.15. Cyclo Therapeutics has a 1 year low of $0.68 and a 1 year high of $2.57.

Cyclo Therapeutics (NASDAQ:CYTH) last announced its quarterly earnings results on Monday, March 18th. The company reported ($0.23) earnings per share (EPS) for the quarter. The business had revenue of $0.31 million during the quarter. Cyclo Therapeutics had a negative net margin of 1,864.03% and a negative return on equity of 4,506.97%.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund VI Management LLC acquired a new position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 110,023 shares of the company’s stock, valued at approximately $175,000. Cyclo Therapeutics comprises approximately 1.4% of Founders Fund VI Management LLC’s portfolio, making the stock its 2nd biggest holding. Founders Fund VI Management LLC owned approximately 0.48% of Cyclo Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 68.55% of the company’s stock.

Cyclo Therapeutics Company Profile

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.